Clinical trial

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected…

NCT00002436 · Glaxo Wellcome, Industry · Completed

Key facts

NCT number NCT00002436
Title The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
Official title A Randomized Lamivudine (3TC)/Dideoxycytidine (ddC) Double-Blind Multicenter Trial (With Open-Label AZT) to Evaluate the Safety and Efficacy of Low Dose 3TC Administered Concurrently With AZT Versus High Dose 3TC Administered Concurrently With AZT Versus ddC Administered Concurrently With AZT in the…
Lead sponsor Glaxo Wellcome, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Lamivudine, Zidovudine, Zalcitabine
Enrollment 325
First posted Aug 31, 2001
Last update posted Jun 24, 2005
Countries Canada, Puerto Rico, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies